Chronic hepatitis C
Conditions
Interventions
PegIFN-alpha2a plus ribavirin
PegIFN-alpha2b plus ribavirin
Sponsors
Hiroshima liver study group
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Naive case 2) genotype 1 and high pretreatment viremia 3) postmenopausal women
Exclusion criteria
Exclusion criteria: 1) Patients receiving shosaiko-to 2) Autoimmune hepatitis 3) History of hypersensitivity to PEG-IFN alpha-2a and PEG-IFN alpha-2b 4) History of hypersensitivity to biological products such as vaccine 5) Decompenstated liver cirrhosis 6) HCC, malignat tumor 7) With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 8) Pregnant or lactating women and women who may be pregnant 9) Judged by investigator not to be appropriate for inclusion in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| virologic response at 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Sustained virologic response Safety ( moniterd clinical and laboratory evaluation) | — |
Countries
Japan
Contacts
Public ContactYoshiiku Kawakami
graduate school of biomedical science, Hiroshima university Department and medicine and molecular science
Outcome results
None listed